DOW JONES27,952.56-1039.85 -3.59%
S&P 5003,219.00-118.75 -3.56%
NASDAQ9,225.83-350.76 -3.66%

U.S. FDA Grants Priority Review For Kite's KTE-X19 Biologics License Application In Relapsed Or Refractory Mantle Cell Lymphoma; NOTE: Kite Is A Gilead Co.

Kite, a Gilead Company (NASDAQ:GILD), today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) and granted Priority Review designation for KTE-X19, an

Benzinga · 02/10/2020 13:31

Kite, a Gilead Company (NASDAQ:GILD), today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) and granted Priority Review designation for KTE-X19, an investigational chimeric antigen receptor (CAR) T cell therapy for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).

The BLA is supported by data from the single arm, open-label, Phase 2 ZUMA-2 trial, which showed that 93 percent of patients responded to a single infusion of KTE-X19, including 67 percent of patients achieving a complete response, as assessed by an Independent Radiologic Review Committee (IRRC; median follow-up of 12.3 months). In the safety analysis, Grade 3 or higher cytokine release syndrome (CRS) and neurologic events were seen in 15 percent and 31 percent of patients, respectively. No Grade 5 CRS or neurologic events occurred. Detailed findings from this trial were recently presented during an oral session at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando.